Recent News and Articles on the Keywords: cancer + hormone + resistance  Related to the article below (Last Update: 8/7/2008)

InjuryBoard.com Monsanto Dairy Hormone Division For Sale Amid Consumer Concerns InjuryBoard.com, FL - Bacterial resistance to antibiotics ?may pass into humans through milk, air, water or soil, or through ground meat", says Michael Hansen, a senior scientist ... Those resistant to hormonal therapy could benefit from new treatment Irish Times, Ireland - Jul 22, 2008 Depriving the body of androgens (testosterone) may slow the spread of prostate cancer. But some men are either resistant to hormonal therapy or its effects ... New Gene Combination May Cause Deadly Prostate Cancer Medical News Today (press release) all 2 news articles » BBC News Prostate Cancer Vaccines with Subsequent Hormone Therapy Found to ... Medi News Direct, India - Jul 23, 2008 Successful replication of these results in phase III trials could be a major breakthrough in treatment options for castrate-resistant prostate cancer. 1. ... New prostate drug 'adds years to life' The Age Pioneering drug offers hope to prostate cancer sufferers ? but not ... Scotsman Govt watching trials of new cancer drug Otago Daily Times NHS Choices - Medical News Today all 491 news articles » Ariad Starts Phase II Study for Breast Cancer FDA news (subscription), VA - Aug 5, 2008 ... HER2-positive breast cancer who have developed resistance to trastuzumab therapy, and will take place at 15 medical centers in the US and Europe. ...ARIA Diatos Launches Two International Multi-center Phase II Clinical ... PharmaLive.com (press release), PA - Aug 5, 2008 Two international trials will evaluate the safety and efficacy of DTS-201 as a second line therapy for patients with hormone refractory prostate cancer and ... Castration-Resistant Prostate Cancer Medscape (subscription) - Jul 18, 2008 At what point are patients truly resistant to hormonal manipulations? Dr. Slovin: Prostate cancer is a progressive disease. Over time, the cancer cells ... ARIAD Announces Start of Phase 2 Clinical Trial of Oral ... MarketWatch - Jul 30, 2008 HER2-positive breast cancers tend to be more aggressive than other types of breast cancer. They're also less responsive to hormone treatment. ... Hollis-Eden Pharmaceuticals Commences Phase I/II Clinical Trial ... Business Wire (press release) all 19 news articles »  HEPH New prostate drug Abiraterone on clinical trials Irish Times, Ireland - Jul 28, 2008 This trial confirms that castration-resistant prostate cancer commonly remains hormone driven. Abiraterone uses a different method from conventional ... HealthJockey.com New Treatment For Advanced Prostate Cancer Science Daily (press release) - Jul 29, 2008 However, despite an initial response, resistance to hormone deprivation often occurs and the tumour starts to grow again, Professor Tilley says. ... A novel treatment for advanced prostate cancer HealthJockey.com Researchers Develop New Treatment For Prostate Cancer TopNews all 34 news articles » Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD ... RedOrbit, TX - Aug 1, 2008 Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors, and is being studied in multiple cancer indications, ...PARD

Inflammatory reaction drives hormone resistance in cancer

Researchers have reported new evidence to explain why prostate cancer and other hormone-dependent cancers may become resistant to hormone therapies.
Their findings further suggest that a similar mechanism may play an essential role in reproductive physiology, including critical events of pregnancy.

Led by Michael Rosenfeld and David Rose at the University of California, San Diego, the group found in studies of cell cultures that so - called macrophages -- components of the innate immune system that drive inflammatory reactions -- physically interact with prostate cancer cells.
That interaction, in turn, reverses the activity of hormone receptors in cancer cells that respond to androgens, such as testosterone, leading to shifts in the expression of other genes.
The study's co-first authors were Ping Zhu and Sung Hee Baek, also of UCSD.

" While hormone resistance can likely be acquired in multiple ways, it appears we may have uncovered a general contributor to hormone resistance in prostate cancer," Rosenfeld said.

" Hormone resistance is a particular problem in prostate cancer, where it occurs in a very high percentage of cases," Rose added. " We think we've now made a connection between inflammation and resistance to particular cancer drugs."

Androgens, acting via androgen receptors, are essential for normal growth and function of the prostate gland and have been implicated in the progression of prostate cancer.
Selective androgen receptor modulators ( SARMs ) are therefore standard treatment for prostate cancer.
However, prostate cancers often become resistant to such treatment. A similar, though less common, phenomenon can also occur in breast cancers treated with drugs that target the hormone receptor for estrogen.

The study reported that an inflammatory chemical produced by macrophages can lead to resistance by setting in motion other changes that reverse the function of SARMs. Those alterations, in effect, turn the androgen receptor-inhibiting drugs into activators.

" This is the last thing you want because that makes the prostate and cancer grow," Rosenfeld said.

Macrophage cells of the immune system infiltrate virtually all prostate tumor samples, the researchers found. They further showed that blocking one of the major chemicals secreted by macrophages prevented SARMs from stimulating androgen receptors, evidence that the inflammatory chemical plays a critical role in the development of drug resistance.

That chemical interaction depends on a portion of the androgen receptor that is specific to all sex steroid receptors, including the estrogen and progesterone receptors, they reported. That region of the receptor is responsible for enlisting a protein that senses inflammatory signals, enabling SARMs to activate genes normally stimulated by active hormone receptors, according to the researchers.

The findings suggest "some very inviting potential" targets for drugs that might prevent the development of hormone resistance in cancers, Rosenfeld said. However, the researchers urge caution as any such advances would take considerably more study.

They point out that the results extend the potential role of macrophages in diseases. For example, earlier studies by the researchers suggested a similar mechanism whereby macrophages in fat cells may lead to insulin resistance, Rose said. Macrophages also have clear roles in atherosclerosis, they added.

The unexpected findings also led the group to a perplexing question. " What is the evolutionary reason for this physiological mechanism ? " Rose asked. " It certainly didn't arise in the context of hormone-resistant cancers."

The researchers uncovered preliminary evidence to suggest that macrophages may induce important reversals in the gene activity regulated by an estrogen hormone in a similar fashion. The mechanism may therefore play a role in gene expression changes associated with the implantation of a fertilized egg in the uterus, they suggest, a process which constitutes an 'inflammatory event,' they said.

" Local inflammation in response to tissue accumulation of macrophages and other immune cells precedes every major reproductive event in the ovaries and uterus, from ovulation to implantation and menstruation," wrote Malcolm Parker of Imperial College London in a preview. The current study suggests that infiltrating macrophage cells may provide signals for "local expression of genes otherwise repressed by sex hormone receptors."

Such mechanisms may play an important role in various reproductive processes, such as the induction of muscle contractions characteristic of labor, Parker added. The process may therefore have important implications for understanding reproductive disorders, such as preterm labor, he suggested.

Source: Cell, 2006